<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Protein kinase-B (AKT) is a serine/threonine protein kinase that has a key role in cell proliferation and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell invasiveness </plain></SENT>
<SENT sid="1" pm="."><plain>Four cardiac <z:chebi fb="0" ids="25905">peptide hormones</z:chebi>, namely vessel dilator, atrial natriuretic <z:chebi fb="7" ids="16670">peptide</z:chebi> (ANP), kaliuretic <z:chebi fb="7" ids="16670">peptide</z:chebi>, and long-acting natriuretic <z:chebi fb="7" ids="16670">peptide</z:chebi> (LANP) have anticancer effects both in vitro and in vivo </plain></SENT>
<SENT sid="2" pm="."><plain>MATERIALS AND METHODS: Four cardiac hormones were examined for their ability to inhibit AKT, measured with a solid-phase enzyme-linked immunosorbent assay (ELISA) in human colorectal, pancreatic, and <z:e sem="disease" ids="C0740457" disease_type="Neoplastic Process" abbrv="">renal cancer</z:e> cells </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Vessel dilator, kaliuretic <z:chebi fb="7" ids="16670">peptide</z:chebi>, ANP, and LANP maximally reduced the concentration of AKT by 47%, 45%, 52%, and 46% in human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells (p&lt;0.0001), by 60%, 61%, 64%, and 59% in human pancreatic <z:mp ids='MP_0002038'>carcinoma</z:mp> cells (p&lt;0.0001), and by 31%, 32%, 31%, and 31% in renal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> cells (p&lt;0.001) </plain></SENT>
<SENT sid="4" pm="."><plain>CONCLUSION: These four cardiac hormones are significant inhibitors of AKT in human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells, as part of their anticancer mechanism(s) of action </plain></SENT>
</text></document>